Our Big Mission:
THE RELENTLESS PURSUIT OF A COMPLETE & PERMANENT CURE FOR EWING SARCOMA.
Why We Exist:
We fund projects and research that have a high potential for saving kids’ lives, period.
Ewing Sarcoma is An Aggressive Bone Cancer Affecting Kids & Young Adults
No Known Cause
Ewing Sarcoma has no hereditary or known environmental cause. It’s a sneaky, random tumor that occurs when normal cellular behavior goes haywire.
Outdated & Toxic Therapy
The treatment for Ewing Sarcoma hasn’t changed in nearly 40 years. It includes the most toxic chemotherapy drugs on the market.
Unacceptable
Despite the aggressive treatment, the prognosis for Ewing Sarcoma is unacceptable. Advances in cancer treatment are not trickling down to kids.
You Can’t Unknow It.
When 9-year-old Lucy was diagnosed with Ewing Sarcoma in September 2019, our world changed forever. We snapped into solution mode: how do we make this go away, forever?
We met with her medical team. And then the second sucker punch came:
The tools to fight this are over 30 years old.
The prognosis for metastatic disease has not improved in 30 years.
As parents, we were faced with the gutting reality that the “current” standard of care is terrifyingly inadequate and entirely unacceptable.
It’s true. It’s awful. And it is absolutely unfair.
In the race for a cure, our kids are being left behind.
Today’s Trials
Tomorrow’s Cure.
There are bright spots on the horizon — emerging therapies that hold great promise to be more effective and efficient.
But we can’t wait for government funding. These advancements are being funded by the families, friends, and communities of our little warriors.
We’re inspired and moved to create a new reality for every warrior and every family staring down a Ewing Sarcoma diagnosis.
When it comes to cancer, there are no “other people’s kids.” Their battle is our battle.
We ask that you join in the fight by giving what you can. 100% of the funds we raise go to high-potential therapies, research, and trials.


In 2025–2026, the Little Warrior Foundation (LWF) is proud to announce a $700,000 grant to the Beat Childhood Cancer Foundation to support the launch of three new clinical trials, including two focused on DFMO with the Beat Childhood Cancer Research Consortium (BCCRC.)